Of course it will also impact insurance premiums most likely, because the insurance companies are going to be paying out larger amounts of money to cover people's drug costs. The interesting thing is that after patent protection was extended as a result of NAFTA, brand-name manufacturers pledged to invest 10% of their sales earnings in research and development in return for the patent extension. Since about 2002, they've consistently failed to meet that commitment, so it's not a good arrangement in any way.
On September 27th, 2016. See this statement in context.